Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in Northern China

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 5, 2010, Pages 759-765

  Li, Ting ^a   Medeiros, L Jeffrey ^b   Lin, Pei ^b   Yin, Hongfang ^a   Littlejohn, Martin ^b   Im, Whan ^b   Lennon, P Alan ^b   Hu, Peter ^b   Jorgensen, Jeffrey L ^b   Liang, Mei ^b   Guo, Hua ^a   Yin, C Cameron ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR-4; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CHINA; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; GERMINAL CENTER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; CHINA; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; INTERFERON REGULATORY FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; TISSUE ARRAY ANALYSIS;

EID: 77952083286     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Stein H, Chan JKC, Warnke RA, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:233-237. WHO Classification of Tumours; vol 2.
2. Tibiletti MG, Martin V, Bernasconi B, et al. BCL2, BCL6, MYC, MALT1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol. 2009;40(5):645-652.
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types ofdiffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
4. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
5. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74.
6. Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101(1):78-84.
7. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-basedmethod todiagnoseclinicallydistinctsubgroups ofdiffuselarge B-cell lymphoma. Proc Natl AcadSci U S A. 2003;100(17):9991-9996.
8. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S41-S47.
9. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001;98(4):945-591.
10. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification ofdiffuse large B-cell lymphoma by immunohistochem- istry using a tissue microarray. Blood. 2004;103(1):275-282.
11. Van Imhoff GW, Boerma EJG, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(25):4135-4142.
12. Berard CW, Greene MH, Jaffe ES, Magrath I, Ziegler J. NIH conference: a multidisciplinary approach to non-Hodgkin's lymphoma. Ann Intern Med. 1981; 94(2):218-235.
13. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998; 9(7):717-720.
14. Ho FC, Todd D, Loke SL, Ng RP, Khoo RK. Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients: retrospective study covering an eight-year period. Int J Cancer. 1984;34(2):143-148.
15. Harrington DS, Ye YL, Weisenburger DD, et al. Malignant lymphoma in Nebraska and Guangzhou, China: a comparative study. Hum Pathol. 1987;18(9): 924-928.
16. Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood. 2002;99(12): 4265-4275.
17. Yin CC, Medeiros LJ, Cromwell CC, et al. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma. Mod Pathol. 2007;20(1):1-7.
18. Yin CC, Medeiros LJ, Glassman AB, Lin P. t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia. Am J Clin Pathol. 2004;121(6):836-842.
19. Kusumoto S, Kobayashi U, Sekiguchi N, et al. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a ''non-germinal center phenotype.'' Am J Surg Pathol. 2005;29(8):1067- 1073.
20. Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005;106(5):1770-1777.
21. Carreon JD, Morton LM, Devesa SS, et al. Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996-2004. Cancer Causes Control. 2008;19(10):1171-1181.
22. Pasqualucci L, Bereschenko O, Niu H, et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma. 2003;44(suppl 3): S5-S12.
23. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86(1):45-53.
24. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16(2): 161-170.
25. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the international prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99(4):1136-1143.
26. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):961-968.
27. Muris JJ, Meijer CJ, vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208(5):714-723.
28. Park CK, Oh YH. Expression of p63 in reactive hyperplasias and malignant lymphomas. J Korean Med Sci. 2005;20(5):752-758.
29. Hedvat CV, Teruya-Feldstein J, Puig P, et al. Expression of p63 in diffuse large B cell lymphoma. Appl Immunohistochem Mol Morphol. 2005;13(3):237-242.
30. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8(2):494-501.
31. Hallack Neto AE, Siqueira SAC, Dulley FL, Ruiz MA, Chamone DAF, Pereira J. p63 protein expression in high risk diffuse large B-cell lymphoma. J Clin Pathol. 2009;62(1):77-79.